Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594257 | 1.00 | CHRNA7 (0.40) | CHRNA7CHRNB2CHRNA4KDM4EBLM | |
| SCHEMBL7589466 | 0.81 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNA4KDM4EBLM | |
| SCHEMBL27473681 | 0.81 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNA4KDM4EBLM | |
| SCHEMBL7589470 | 0.81 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNA4KDM4EBLM | |
| SCHEMBL7684465 | 0.80 | CHRNA7 (0.46) | CHRNA7CHRNB2CHRNA4KDM4EBLM | |
| SCHEMBL7590540 | 0.80 | CHRNA7 (0.46) | CHRNA7CHRNB2CHRNA4KDM4EBLM | |
| SCHEMBL7681930 | 0.77 | CHRNA7 (0.43) | CHRNA7CHRNB2CHRNA4KDM4EBLM | |
| SCHEMBL7594374 | 0.77 | CHRNA7 (0.43) | CHRNA7CHRNB2CHRNA4KDM4EBLM | |
| SCHEMBL7679889 | 0.73 | CHRNA7 (0.52) | CHRNA7CHRNB2CHRNA4KDM4EBLM | |
| SCHEMBL7590744 | 0.72 | KDM4E (0.46) | CHRNA7CHRNB2CHRNA4KDM4EBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6451789-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | LES LABORTOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | RAULT SYLVAIN (FR) | 2002-04-11 | — | — | US | disclosed |
| US-6323222-B1 | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | SULT2A1, GRIN2A, NR3C1 | CHRNA7 150/4885CHRNB2 344/4885CHRNA4 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.